-
Mashup Score: 23Symposium | BCMA-directed bispecific antibodies - 8 day(s) ago
During the Multiple Myeloma Hub virtual symposium, Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on BCMA-directed bispecific antibodies in MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Session 6: Insights from Health Care Systems on Bispecifics: Patient Treatment, Monitoring and Transition of Care - 11 month(s) ago
Binod Dhakal, MD, MS, and a panel of experts in multiple myeloma provide a look at an upcoming Cancer Network Training Academy program discussing how to incorporate bispecific antibodies in the treatment of multiple myeloma, and how healthcare systems implement step-up dosing, treatment doses and transition of care. The panel also offers insights into the recommended strategies for monitoring…
Source: Cancer NetworkCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Infection incidence with CAR T-cell and bispecific antibody therapies - 12 month(s) ago
We summarize a presentation from the 4th Immune Effector Cell Therapies in Multiple Myeloma Workshop on infection incidence associated with CAR T-cell and bispecific antibody therapies.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities - 1 year(s) ago
Falchi and colleagues review the development of and clinical experience with bispecific antibodies, a class of T-cell redirecting drugs with excellent activity
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4
This article summarizes the updated safety, overall response, and response durability in patients treated in the phase I dose-escalation part of the trial, presented at the 63rd ASH Annual Meeting and Exposition by Jeffrey Zonder.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals - 2 year(s) ago
Key Points. Continuous exposure to a CD19xCD3 bispecific molecule induces T-cell exhaustionTreatment-free intervals transcriptionally reprogram and functionally
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements - 2 year(s) ago
Zenocutuzumab, a HER2xHER3 bispecific antibody, reduces cell growth in NRG1-rearranged cancer cell lines and xenografts and induces durable clinical responses in patients with NRG1 fusion–positive tumors.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
This article summarizes the updated safety, overall response, and response durability in patients treated in the phase I dose-escalation part of the trial, presented at the 63rd ASH Annual Meeting and Exposition by Jeffrey Zonder.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements - 2 year(s) ago
Abstract. NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream signaling, and tumorigenesis. Targeting ERBBs, therefore, represents a therapeutic strategy for these cancers. We investigated zenocutuzumab (Zeno, MCLA-128), an ADCC-enhanced anti-HER2xHER3 bispecific antibody, in NRG1…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 9Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements - 2 year(s) ago
NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream signaling, and tumorigenesis. Targeting ERBBs, therefore, represents a therapeutic strategy for these cancers. We investigated zenocutuzumab (Zeno, MCLA-128), an ADCC-enhanced anti-HER2xHER3 bispecific antibody, in NRG1…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
In our recent symposium, Naresh Bumma delved into BCMA-directed #bispecific antibodies for MM. “We need to consider patient-specific clinical factors. Access is very important, and obviously patient preference is very important.” Catch up below 👇 https://t.co/TunXO7MHUG https://t.co/kEoaJwZphF